# Halozyme Therapeutics, Inc.: financial statements, quarterly

HALO · Nasdaq · CIK 1159036 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/halo.md) · [Financials](/companies/halo/financials.md) · [Filings](/companies/halo/filings.md) · [Insiders](/companies/halo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/halo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [216](/filings/0001159036-24-000050.md) | [230 d](/filings/0001159036-26-000024.md) | [196](/filings/0001159036-25-000026.md) | [231](/filings/0001159036-25-000034.md) | [290](/filings/0001159036-25-000045.md) | [298 d](/filings/0001159036-26-000024.md) | [265](/filings/0001159036-26-000068.md) | [326](/filings/0001159036-26-000104.md) | [354](/filings/0001159036-25-000045.md) | [452 d](/filings/0001159036-26-000024.md) | [377](/filings/0001159036-26-000068.md) | [481](/filings/0001159036-26-000104.md) |
| Cost of revenue | $m | [54.8](/filings/0001159036-24-000050.md) | [52.3 d](/filings/0001159036-26-000024.md) | [28.3](/filings/0001159036-25-000026.md) | [39.6](/filings/0001159036-25-000034.md) | [49.4](/filings/0001159036-25-000045.md) | [42.1 d](/filings/0001159036-26-000024.md) | [48.4](/filings/0001159036-26-000068.md) | [46.4](/filings/0001159036-26-000104.md) | [55.2](/filings/0001159036-25-000045.md) | [78.8 d](/filings/0001159036-26-000024.md) | [79.2](/filings/0001159036-26-000068.md) | [79.2](/filings/0001159036-26-000104.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [17.3](/filings/0001159036-24-000050.md) | [21.3 d](/filings/0001159036-25-000010.md) | [19.1](/filings/0001159036-25-000026.md) | [21.0](/filings/0001159036-25-000034.md) | [18.5](/filings/0001159036-25-000045.md) | [20.4 d](/filings/0001159036-25-000010.md) | [14.8](/filings/0001159036-26-000068.md) | [17.5](/filings/0001159036-26-000104.md) | [17.3](/filings/0001159036-25-000045.md) | not reported | [25.6](/filings/0001159036-26-000068.md) | [27.7](/filings/0001159036-26-000104.md) |
| Selling, general and administrative | $m | [35.3](/filings/0001159036-24-000050.md) | [37.6 d](/filings/0001159036-26-000024.md) | [35.1](/filings/0001159036-25-000026.md) | [35.7](/filings/0001159036-25-000034.md) | [41.2](/filings/0001159036-25-000045.md) | [42.2 d](/filings/0001159036-26-000024.md) | [42.4](/filings/0001159036-26-000068.md) | [41.6](/filings/0001159036-26-000104.md) | [46.1](/filings/0001159036-25-000045.md) | [77.0 d](/filings/0001159036-26-000024.md) | [57.9](/filings/0001159036-26-000068.md) | [57.0](/filings/0001159036-26-000104.md) |
| Operating income | $m | [88.3](/filings/0001159036-24-000050.md) | [101 d](/filings/0001159036-26-000024.md) | [95.5](/filings/0001159036-25-000026.md) | [117](/filings/0001159036-25-000034.md) | [163](/filings/0001159036-25-000045.md) | [176 d](/filings/0001159036-26-000024.md) | [142](/filings/0001159036-26-000068.md) | [202](/filings/0001159036-26-000104.md) | [218](/filings/0001159036-25-000045.md) | [(92.9) d](/filings/0001159036-26-000024.md) | [185](/filings/0001159036-26-000068.md) | [288](/filings/0001159036-26-000104.md) |
| Interest expense | $m | [4.5](/filings/0001159036-23-000057.md) | [5.2 d](/filings/0001159036-24-000008.md) | [4.5](/filings/0001159036-24-000037.md) | [4.5](/filings/0001159036-25-000034.md) | [4.5](/filings/0001159036-25-000045.md) | [4.5 d](/filings/0001159036-26-000024.md) | [4.5](/filings/0001159036-26-000068.md) | [4.4](/filings/0001159036-26-000104.md) | [4.3](/filings/0001159036-25-000045.md) | [4.9 d](/filings/0001159036-26-000024.md) | [5.5](/filings/0001159036-26-000068.md) | [5.6](/filings/0001159036-26-000104.md) |
| Income tax | $m | [19.9](/filings/0001159036-24-000050.md) | [15.8 d](/filings/0001159036-26-000024.md) | [19.2](/filings/0001159036-25-000026.md) | [24.5](/filings/0001159036-25-000034.md) | [28.1](/filings/0001159036-25-000045.md) | [41.2 d](/filings/0001159036-26-000024.md) | [25.7](/filings/0001159036-26-000068.md) | [39.8](/filings/0001159036-26-000104.md) | [43.7](/filings/0001159036-25-000045.md) | [40.7 d](/filings/0001159036-26-000024.md) | [30.3](/filings/0001159036-26-000068.md) | [55.0](/filings/0001159036-26-000104.md) |
| Net income | $m | [81.8](/filings/0001159036-24-000050.md) | [85.4 d](/filings/0001159036-26-000024.md) | [76.8](/filings/0001159036-25-000026.md) | [93.2](/filings/0001159036-25-000034.md) | [137](/filings/0001159036-25-000045.md) | [137 d](/filings/0001159036-26-000024.md) | [118](/filings/0001159036-26-000068.md) | [165](/filings/0001159036-26-000104.md) | [175](/filings/0001159036-25-000045.md) | [(142) d](/filings/0001159036-26-000024.md) | [150](/filings/0001159036-26-000068.md) | [230](/filings/0001159036-26-000104.md) |
| Diluted EPS | $ per share | [0.61](/filings/0001159036-24-000050.md) | not reported | [0.60](/filings/0001159036-25-000026.md) | [0.72](/filings/0001159036-25-000034.md) | [1.05](/filings/0001159036-25-000045.md) | not reported | [0.93](/filings/0001159036-26-000068.md) | [1.33](/filings/0001159036-26-000104.md) | [1.43](/filings/0001159036-25-000045.md) | not reported | [1.22](/filings/0001159036-26-000068.md) | [1.90](/filings/0001159036-26-000104.md) |
| Basic EPS | $ per share | [0.62](/filings/0001159036-24-000050.md) | not reported | [0.61](/filings/0001159036-25-000026.md) | [0.73](/filings/0001159036-25-000034.md) | [1.08](/filings/0001159036-25-000045.md) | not reported | [0.96](/filings/0001159036-26-000068.md) | [1.36](/filings/0001159036-26-000104.md) | [1.49](/filings/0001159036-25-000045.md) | not reported | [1.27](/filings/0001159036-26-000068.md) | [1.96](/filings/0001159036-26-000104.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [274](/filings/0001159036-23-000057.md) | [118](/filings/0001159036-26-000024.md) | [165](/filings/0001159036-24-000037.md) | [188](/filings/0001159036-24-000044.md) | [154](/filings/0001159036-24-000050.md) | [116](/filings/0001159036-26-000024.md) | [176](/filings/0001159036-26-000068.md) | [61.9](/filings/0001159036-26-000104.md) | [420](/filings/0001159036-25-000045.md) | [134](/filings/0001159036-26-000104.md) | [310](/filings/0001159036-26-000068.md) | [163](/filings/0001159036-26-000104.md) |
| Current assets | $m | [879](/filings/0001159036-23-000057.md) | [746](/filings/0001159036-25-000010.md) | [874](/filings/0001159036-24-000037.md) | [988](/filings/0001159036-24-000044.md) | [1,127](/filings/0001159036-24-000050.md) | [1,085](/filings/0001159036-26-000024.md) | [1,262](/filings/0001159036-25-000026.md) | [1,123](/filings/0001159036-25-000034.md) | [1,329](/filings/0001159036-25-000045.md) | [825](/filings/0001159036-26-000104.md) | [1,003](/filings/0001159036-26-000068.md) | [933](/filings/0001159036-26-000104.md) |
| Total assets | $m | [1,893](/filings/0001159036-23-000057.md) | [1,733](/filings/0001159036-25-000010.md) | [1,842](/filings/0001159036-24-000037.md) | [1,969](/filings/0001159036-24-000044.md) | [2,118](/filings/0001159036-24-000050.md) | [2,063](/filings/0001159036-26-000024.md) | [2,197](/filings/0001159036-25-000026.md) | [2,054](/filings/0001159036-25-000034.md) | [2,221](/filings/0001159036-25-000045.md) | [2,525](/filings/0001159036-26-000104.md) | [2,673](/filings/0001159036-26-000068.md) | [2,577](/filings/0001159036-26-000104.md) |
| Current liabilities | $m | [115](/filings/0001159036-23-000057.md) | [112](/filings/0001159036-25-000010.md) | [132](/filings/0001159036-24-000037.md) | [133](/filings/0001159036-24-000044.md) | [109](/filings/0001159036-24-000050.md) | [139](/filings/0001159036-26-000024.md) | [150](/filings/0001159036-25-000026.md) | [134](/filings/0001159036-25-000034.md) | [837](/filings/0001159036-25-000045.md) | [177](/filings/0001159036-26-000104.md) | [363](/filings/0001159036-26-000068.md) | [344](/filings/0001159036-26-000104.md) |
| Total liabilities | $m | [1,643](/filings/0001159036-23-000057.md) | [1,649](/filings/0001159036-25-000010.md) | [1,664](/filings/0001159036-24-000037.md) | [1,680](/filings/0001159036-24-000044.md) | [1,665](/filings/0001159036-24-000050.md) | [1,700](/filings/0001159036-26-000024.md) | [1,714](/filings/0001159036-25-000026.md) | [1,721](/filings/0001159036-25-000034.md) | [1,717](/filings/0001159036-25-000045.md) | [2,477](/filings/0001159036-26-000104.md) | [2,453](/filings/0001159036-26-000068.md) | [2,434](/filings/0001159036-26-000104.md) |
| Long-term debt | $m | [1,498](/filings/0001159036-23-000057.md) | [1,499](/filings/0001159036-25-000010.md) | [1,501](/filings/0001159036-24-000037.md) | [1,503](/filings/0001159036-24-000044.md) | [1,504](/filings/0001159036-24-000050.md) | [1,506](/filings/0001159036-26-000024.md) | [1,507](/filings/0001159036-25-000026.md) | [1,509](/filings/0001159036-25-000034.md) | [800](/filings/0001159036-25-000045.md) | [2,143](/filings/0001159036-26-000104.md) | [1,936](/filings/0001159036-26-000068.md) | [1,938](/filings/0001159036-26-000104.md) |
| Current portion of debt | $m | [0.0](/filings/0001159036-23-000057.md) | [0.0](/filings/0001159036-24-000008.md) | not reported | not reported | not reported | [0.0](/filings/0001159036-25-000045.md) | not reported | not reported | [711](/filings/0001159036-25-000045.md) | [0.0](/filings/0001159036-26-000104.md) | [209](/filings/0001159036-26-000068.md) | [209](/filings/0001159036-26-000104.md) |
| Shareholders' equity | $m | [249](/filings/0001159036-24-000050.md) | [83.8](/filings/0001159036-26-000024.md) | [178](/filings/0001159036-25-000034.md) | [289](/filings/0001159036-25-000045.md) | [453](/filings/0001159036-25-000045.md) | [364](/filings/0001159036-26-000104.md) | [482](/filings/0001159036-26-000104.md) | [333](/filings/0001159036-26-000104.md) | [504](/filings/0001159036-25-000045.md) | [48.8](/filings/0001159036-26-000104.md) | [220](/filings/0001159036-26-000104.md) | [144](/filings/0001159036-26-000104.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [132 d](/filings/0001159036-24-000050.md) | [102 d](/filings/0001159036-26-000024.md) | [129](/filings/0001159036-25-000026.md) | [55.8 d](/filings/0001159036-25-000034.md) | [115 d](/filings/0001159036-25-000045.md) | [178 d](/filings/0001159036-26-000024.md) | [154](/filings/0001159036-26-000068.md) | [99.7 d](/filings/0001159036-26-000104.md) | [179 d](/filings/0001159036-25-000045.md) | [219 d](/filings/0001159036-26-000024.md) | [180](/filings/0001159036-26-000068.md) | [241 d](/filings/0001159036-26-000104.md) |
| Capital expenditure | $m | [2.9 d](/filings/0001159036-24-000050.md) | [2.6 d](/filings/0001159036-26-000024.md) | [3.5](/filings/0001159036-25-000026.md) | [2.6 d](/filings/0001159036-25-000034.md) | [1.5 d](/filings/0001159036-25-000045.md) | [3.1 d](/filings/0001159036-26-000024.md) | [1.0](/filings/0001159036-26-000068.md) | [1.6 d](/filings/0001159036-26-000104.md) | [3.0 d](/filings/0001159036-25-000045.md) | [1.4 d](/filings/0001159036-26-000024.md) | [3.7](/filings/0001159036-26-000068.md) | [4.2 d](/filings/0001159036-26-000104.md) |
| Share repurchases | $m | [0.0 d](/filings/0001159036-24-000050.md) | [252 d](/filings/0001159036-26-000024.md) | [0.0](/filings/0001159036-24-000037.md) | [0.0 d](/filings/0001159036-25-000034.md) | [0.0 d](/filings/0001159036-25-000045.md) | [250 d](/filings/0001159036-26-000024.md) | not reported | not reported | [38.9 d](/filings/0001159036-25-000045.md) | [0.0 d](/filings/0001159036-26-000024.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [139](/filings/0001159036-23-000057.md) | [138](/filings/0001159036-24-000037.md) | [134](/filings/0001159036-24-000044.md) | [134](/filings/0001159036-24-000050.md) | [129](/filings/0001159036-25-000026.md) | [129](/filings/0001159036-25-000034.md) | [130](/filings/0001159036-25-000045.md) | [127](/filings/0001159036-26-000068.md) | [124](/filings/0001159036-26-000104.md) | [122](/filings/0001159036-25-000045.md) | [123](/filings/0001159036-26-000068.md) | [121](/filings/0001159036-26-000104.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 113,498,000 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001159036-26-000104.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.